Integumen Share Price (SKIN)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Integumen Plc LSE:SKIN London Ordinary Share GB00BMGWZY29 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 28.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
28.00 29.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Personal Goods 0.82 -2.40 0.30 93.3 32
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 28.00 GBX
Related Shares
Burberry (BRBY), Pz Cussons (PZC), Eve Sleep (EVE), Pittards (PTD)

Integumen (SKIN) Latest News

Integumen News

Date Time Source Headline
26/7/202112:25UKREGDeepverge PLC Result of AGM
26/7/202107:00UKREGDeepverge PLC Update
12/7/202107:00RNSNONDeepverge PLC Appointment of Group Marketing Officer
07/7/202113:16UKREGDeepverge PLC Exercise of Options and Total Voting Rights
30/6/202117:29UKREGDeepverge PLC Notice of AGM
30/6/202117:28UKREGDeepverge PLC Final Results
25/6/202114:55UKREGDeepverge PLC Holding(s) in Company
24/6/202107:00UKREGDeepverge PLC Microtox Successful Phase 3 Field Trials
23/6/202113:15UKREGDeepverge PLC Result of General Meeting
07/6/202112:23UKREGDeepverge PLC GBP10m Firm /Cond'l Placings & Subs - replacement
More Integumen News
Integumen Investors    Integumen Takeover Rumours

Integumen (SKIN) Discussions and Chat

Integumen Forums and Chat

Date Time Title Posts
06/10/202012:48Integumen - Skin in the Game13,520
29/9/202016:16True Judaism a means to a co-existance with Non-Jews19
12/7/201907:51Integumen82
06/4/201711:44Skin in the Game2

Add a New Thread

Integumen (SKIN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Integumen trades in real-time

Integumen (SKIN) Top Chat Posts

DateSubject
28/7/2021
09:20		Integumen Daily Update: Integumen Plc is listed in the Personal Goods sector of the London Stock Exchange with ticker SKIN. The last closing price for Integumen was 28p.
Integumen Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 64p while the 1 year low share price is currently 19p.
There are currently 113,534,451 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Integumen Plc is £31,789,646.28.
Read Full Thread
Reply
01/10/2020
11:30		monkey puzzle: hxxp://www.global-engage.com/event/labskin-virtual-lab-tour/ Combining the Labskin lab-grown 3D skin models and Labskin’s ability to harvest and replicate the skin microbiome of a human volunteer, the Remote Clinical Trial platform is an innovative, problem-solving platform which guarantees accurate, socially-distanced product-testing capabilities for cosmetics and skin care brands. During the webinar Paul Ryan and Alex Chapman will take you through the Labskin laboratory facility in the UK with a virtual tour, followed by an in-depth presentation of the Remote Clinical Trial platform and a case study that will guide you through the Remote Clinical Trial journey from a client perspective. A live and moderated Q&A session will close out the webinar, and questions can be directed here. Date: 20 October 2020 Time: New York – 11:00 | London – 16:00 | Paris – 17:00 | Singapore – 23:00 |Tokyo – 00: 00 (21 October) |Sydney – 01:00 (21 October) Duration: 75 minutes Event structure: Virtual lab tour, 2 presentations and Q&A Registration fee: Complimentary access Webinar on-demand: Available to view until midnight 4 November 2020 (registration is required) Labskin’s pioneering approach to testing skin care products by cloning a patient’s skin microbiome and transplanting it on to Labskin human skin equivalent allows a wide range of testing that no longer requires invasive procedures on patients. Data from next generation sequencing of the Labskin and skin biome is coupled with AI processes to interpret and direct further development of skincare products in a controlled and efficient manner, reducing development time and costs.
Read Full Thread
Follow
Reply
01/10/2020
07:21		monkey puzzle: RE: A re-imagined look at skin model testing – Q&A with LabskinWed 23:17 2/2 China still mandates that cosmetics safety has to be tested in animals although recent announcements have lifted restrictions on importing cosmetic products with alternative methods for safety assessment. The Chinese regulator is looking to establish alternatives in vitro standards to animal testing. Labskin is in an excellent position to become a key part of the new regulatory environment emerging in the Chinese cosmetics market. In January 2020 Labskin signed a Memorandum of Understanding with the Innocare Group to promote innovation and cooperation on regulatory compliance without animal testing. To make our skin models more relevant to Asian markets, Labskin is collaborating with the University of Bradford to develop a model containing melanocytes so that next-generation skin models can be created using cells from donors with different ethnic backgrounds. Melanin is a natural sink of chemical compounds so different level of pigmentation could become an important factor not only for safety testing and efficacy. Looking ahead 10 or 20 years from now, what does the future hold for the lab–grown human skin model? How far can you go? At this point, there is no limit to what we can do with skin models. The most urgent matter to address is adding extra complexity. This includes the need for melanocytes and Langerhans cells, sourced to improve the immune response of the models. Research demonstrates that this is possible; it just needs to be commercially produced. The next step will be to add complex macrostructures, such as hair follicles, sweat and sebaceous glands, possibly by reprogramming stem cells. Blood vessels could be developed inside a 3D model like Labskin as we know that seeding endothelial cells into a skin model produces a self-organized microvasculature. A combination of these techniques and 3D bioprinting will give rise to a new generation of skin models with blood/lymphatic vessels that could be connected to a microfluidic system, similar to our circulatory system, wired to keep the skin alive. All of this improvement combined with further developments in acute, chronic toxicology and efficacy will result in improved models. hxxps://connect.in-cosmetics.com/news-category/testing-regulations/a-reimagined-look-at-skin-model-testing-qa-with-labskin/ ReplyRecommend (5)Report Post E_AL Premium Member Posts: 2,950 Price: 34.75 No Opinion A re-imagined look at skin model testing – Q&A with LabskinWed 23:16 1SEPTEMBER 29, 2020 1/2 * An interview with David Caballero-Lima, R&D Manager, Labskin Labskin has been around for twelve years – can you tell us about the history of the company as well as your field of expertise? The Labskin model was created by a group of microbiologists at the University of Leeds to study the skin human microbiota and the microbial/host interaction in a controlled environment. Labskin has unique features, including its improved barrier function, dry surface and the expression of antimicrobial peptides which allow the colonization of the model with skin microbiome. We use these defining characteristics to develop methods for testing ingredients and formulations on the microbial community on Labskin. We colonise Labskin with different microbial consortia containing mixes of skin bacteria and fungi. We can also isolate the whole microbiome from volunteers and transplant this microbiome onto Labskin. We can even challenge those consortia or microbiomes with pathogens. Then, combining a range of techniques such as colony counting, RT-qPCR, immunohistochemistry, ELISA or sequencing; we are able to look at the effect of those products on both the host and the microbiota at the same time. We can’t avoid the obligatory question about Covid-19 and testing sanitizers… you collaborate with various universities and academics…any exciting initiatives you can share with us? We regularly carry out tests on skin sanitisers, soaps and cleansers using our commensal skin consortia and specific pathogens. In the lab, our standard methods for testing sanitisers against the virus implement the most robust safety measures. We are now working with two leading universities with Containment Level 3 biosafety levels for specific laboratory work on SARS–CoV2. Most data on the efficacy of hand sanitisers against the Covid-19 virus do not correlate to a real-life situation. We use our Labskin model to get data in an environment that closely resembles real human skin. Additionally, we isolate microbiome from volunteers and have developed methods to isolate those microbiomes without contact with the subject. In effect, we run remote clinical trials that use an internet portal to recruit and send swabs to the volunteers and recover the whole microbiomes from those volunteers to safely transplant them onto our skin models in our facilities.
Read Full Thread
Follow
Reply
26/9/2020
10:46		tickboo: Lunsam on lse-To clear up a couple of points, the share price did not halve because of the AGM, the share price halved because Helium sold 6% of Integumen, pretty much in one go. Traders had already bought in the morning, and so when there were 6 million shares on the bid there was simply not enough demand to take them. Obviously this means they walk down the buy price until someone does buy them. GB had built it up on Twitter, and so had attracted a lot of traders in the prior days, the news was irrelevant to them. These guys who trade for gains of 10-20% in a few days were now down 10-20%, this clearly creates panic and adds to the number of shares being sold. IF there had been no hype on social media platforms, the share price would likely have been at 30p when the BT was announced, it likely would have gone to 70 on the news and Helium would have still sold 6%, taking the price back down. I doubt we would be back down to where we are now, but Helium selling is totally unforeseen and out of Gerrys control. Combined SKIN and MWG (at 65p) represented over 40% of Heliums Portfolio, any decent investors on this board know that that is overexposure to a single company. Per the last disclosure, they own 3.32% of SKIN and 13.55% of MWG. This is c. 8% of the enlarged entity. GB will now realise that what he did on Twitter was partially responsible for the capitulation, he is a large shareholder and so as he said himself, will have noticed. He also doesn't really care for daily share price movements, he is trying to build a large company and will look at this on a 3 year time horizon (or something like that anyway). Genuine excitement got misconstrued, and i would be very surprised to see more minions on Twitter 8 hours before a significant announcement. The fundamentals do remain unchanged, he has grown revenues 400% year on year and is looking at that same multiple this year. Revenue guidance for this half year suggests that we will be on the cusp of EBITDA positive. We have £1m of exercised warrants in the bank, and a £3m debt facility. That is plenty to see the final development of both the above ground, and below ground waste-water test through. They have access to one of the 7 (i think) Category 3 Laboratories in Aberdeen, that is not easy to get access to. He will be in contact with Cruise companies, Airlines, Schools etc. This is the perfect solution for them. He is in contact with multiple Governments (he has no reason to lie about this).Investors (maybe not traders), should look past Covid, and realise how transferable the technology is that is being built. What you can do for one disease, you can do for many others. This is so far from a one trick pony that many on this board seem to think it is. I have total faith that DeepVerge (SKIN + MWG) will be a market leading ESG investment within the Skincare and Water Industry over years to come.
Read Full Thread
Follow
Reply
25/9/2020
22:12		the shuffle man: From GB posted on the LSE BBTwo Years to Get Here - PerspectiveToday 22:02Evening All.As a large shareholder, I have seen the share price drop, and read the frustration in the comments. But a little perspective is needed. Look what has been achieved in the last 2 years. I am not just talking about the share price, which has been a reflection of the turnaround, but the application of technology that has existed for over 12 years in Labskin. 5 years work in Rinocloud and 30+ years in Modern Water monitoring division.We didn't set out to develop a COVID19 solution, we set out to transfer a successful project, developed over 4 years, supported by the Irish Environmental Protection Agency which was a 4 second E. Coli detection in water, and I install it into an base of Microtox equipment in 63 countries around the world.Even as lockdown came in March, we were fixated on and our expertise in bacteria production. It was May when we seen this as much a necessity as an opportunity.We made an offer to acquire MWG and disclosed it one month ago. It is expected to close early November.10+ partner, collaboration, cooperation, sub-contract consortium with Top 20 skincare, pharma, woundcare companies, footprint on 3 continents, and Microtox wastewater equipment being retrofitted with SARS-CoV-2 detection technology. That is going to market in Q1 2021,with interest across the globe. That is in the video if you watch it again.The virus can be detected on the same silicon chips for breath as it can in water. So Aptamers and Affimers have a high sensitivity that we use on the chip. If the virus is captured the alteration in the surface of the chip is detected from our experiments 100%.Now there are hurdles, but not many, and this will be launched in 2021, initially for SARS-CoV-2, but again in the video if the Affimers and Aptamers are raised for other pathogens, it will detect other pathogens (bacteria/viruses).Back to perspective. If you are a long term holder you bought because you did your research and you have conviction and you didn't sell. You didn't lose a cent. Unless you sell now it is ugly to look at but it is a number on your screen today. That will change.If you are a trader and hoped to multi-bag overnight, without doing research, I can't help, as I have a passionate team, who are obsessed and work tirelessly to make a difference that counts and will help everyone.I didn't give you a shiny polished video at the AGM, not because we couldn't have done, but we would prefer to spend the £30,000 on important things for the laboratory. Instead you got 48 hours of man hours, taking the focus of their job, to tell you of their pride in our Company's success.Sorry that was long, but it was written with passion and pride in the team. So chillax we are making a difference and it is being noticed.Last thing is I can't answer over 1000 comments, but I do read, even the angry ones.
Read Full Thread
Follow
Reply
25/9/2020
17:03		montynj: Below is copy and paste from lunsam on Twitter...v useful "Yesterday was a perfect storm. Day-traders looking for the next 'Covid moonshoot', coupled with their a major shareholder, the Helium Rising Stars Fund, selling nearly 6%. Helium only invest to £50m mcap, at 61p/64p where they sold #SKIN + #MWG had a combined mcap of >£100m. Its not within the fund investment strategy to hold companies of that size, which is why they sold. Its a shame it happened yesterday, it created utter panic amongst PIs and what can be only seen as the most ridiculous day of share price movement I have ever seen on AIM. 3/15I see significant value in the 4 core business channels;1. #Labskin - lab-grown human skin, enables remote clinical trials of skincare products, prevents the need of animal testing of skin products. 2. #Rinocloud - artificial intelligence, data management, machine learning 4/153. Water Monitoring - once #MWG is acquired, #DVRG have access to Gold-Standard water monitoring kit, and a worldwide distribution channel.4. Covid Monitoring - below ground and above ground, waste-water community screening, and above ground breath-testing. 5/15These are 4, potentially industry-revolutionising businesses. That is why I invested at in both #SKIN and #MWG at around 1p (10p post consol.). That has not changed. €Rinocloud is what enables the other 3 businesses to be revolutionary. I shall explain why: 6/15Water monitoring has historically been done by sampling, you sample water every few days and test it. Once you find a problem you remedy it, often too late. With the addition of Rinocloud, you have LIVE water monitoring. You detect a problem instantly, as soon as it happens. 7/15With both skin trials and water detection, you create a repository of data/knowledge of research and predictive analysis. You provide time-stamped, validated and reproducible data. You can start to able to predict outcomes using the AI and machine learning. 8/15Re. yesterday and the #Covid19 Testing, we have (that I know of), the worlds only live water monitoring, community-screening Covid monitoring device. This is hugely important as it can track and identify hotspots, collect data and be used to predict outbreaks. 9/15What was announced yesterday, was the first end-to-end Covid testing solution. A system which has community screening, and a time-stamped positive/negative that is available within seconds for £4 a day. #AVCT may be developing another, but we are yet to see it & cost. 10/15Even if the solution announced yesterday is not installed worldwide, it is the perfect solution for the cruise industry, offices, airlines, hospitals and schools. Those are significant potential revenue channels, worth far more than the current £50m mcap in my eyes. 11/15The QR code aspect prevents queues into venues, enables one to go to an event with the peace of mind that they are going to be allowed in. Pregnancy style tests will be hard to timestamp, not reusable and you'd need to wait for the result while someone watches. Queues. 12/15The breathalyser is unique to a given person, it is linked to the app when you buy it. That means that only the person that buys the breathalyser can use it, and someone else can't take the test for them. Another problem with the pregnancy style, unless someone is watching. 13/15Funding: They have >£1m in cash from warrants, and a £3m debt facility - GB has said that this lasts them well into 2021 - there is certainly going to be a lot of news between now and then. Revenues up 400% yoy, and they are on the cusp of being EBITDA positive for H2 2020. 14/15One Snippet from the AGM Q & G. 'Have you engaged with governments?' GB - 'Yes, multiple, not just the UK'. Lets see where it goes, but I get the feeling that there is a lot more to come... 15/15
Read Full Thread
Follow
Reply
24/9/2020
14:05		thetrotsky: Monkey, get real. Criticism where criticism is due. The sun don't shine out of GB's ar$e. The company issued a great RNS and then the share price plummeted during the AGM because of GB's responses. You may criticise those "short term rainbow chasing losers" but at the end of the day they are your meal ticket; if they don't buy, the share price don't go up and, if the share price don't go up, we all end up being losers (even you; okay you can say you're already in profit but if the share price don't go up from here it's just dead money and you should be selling). GB made a booboo today, plain and simple. This bb is supposed to be balanced; if it just ignores the bad then it serves no purpose. Show some integrity.
Read Full Thread
Follow
Reply
24/9/2020
08:36		thetrotsky: I don't think the share price disparity between SKIN and MWG is helping matters; I wouldn't be surprised if some SKIN shareholders are still selling to buy MWG. If you can sell SKIN at (say) 65p and buy MWG at (say) 60p, why not? But it helps blunt any upward momentum in the SKIN price and an at one point this morning the MWG share price actually got ahead of SKIN! The MMs are loving it!
Read Full Thread
Follow
Reply
22/9/2020
11:49		gjbrandon: To clear the confusion. MWG forms a core element to the SKIN strategy going forward. The share price on any day is not the way the deal was constructed. It was a negotiation over 3 months, resulting in a 1 for 1 share at the time (consolidation followed) and share price was considered on a 90 day VWAP (Volume Weighted Average Price) over that period. The reason the shares were not suspended was because it was a share for share. It just so happened that on the publication of the 2.7 Announcement, the share prices was what it was.
Read Full Thread
Follow
Reply
22/9/2020
11:02		turvart: Monkey Puzzle, From what I can make out with my experience is that MWG was offered 4.05p at the last closing price of the takeover announcement, this will then give MWG 34% of DVRG but 1 share of MWG will equal 1 share of DVRG, meaning that MWG is merged with Skin in a new company, but because SKIN had more shares than MWG then skin holds a higher percentage in the merger. What I'm trying to say is that Skin & MWG are equal in price after the merger but because skin has more shares then skin is the larger part of the merger but they are both equal in share price with regards the merger. PS: I forgot to add that when MWG gets merged into DVRG that 10 shares will become 1 share but the share price will rise 10 fold. I hope this clears any confusion.
Read Full Thread
Follow
Reply
22/9/2020
08:45		turvart: Monkey Puzzle, I do fully agree with you however I thought the MM's would of held SKIN share price back due to MWG, IMO they are linked now.
Read Full Thread
Follow
Reply
Integumen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SKIN
Integumen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210729 07:00:18